Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)

Peripheral Arterial Disease Clinical Trial

Official title:

Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02369848
• Other study ID #: TD 0232
• Status: Completed
• Phase: N/A
• First received: February 9, 2015
• Last updated: March 19, 2018
• Start date: June 2015
• Est. completion date: December 2016

Study information

• Verified date: March 2018
• Source: Shockwave Medical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Shockwave Medical, Inc. intends to conduct a prospective, single-arm, multi-center, clinical study designed to evaluate the safety and performance of the Shockwave Lithoplasty™ System in subjects with moderate to heavily calcified peripheral arteries with 3.50mm to 7.0mm reference vessel diameter at the target site. The Shockwave Lithoplasty™ System is indicated to generate sonic shockwave energy within the target treatment site and disrupt calcium within the lesion to allow for subsequent dilation of a peripheral artery stenosis using low balloon pressure. Up to sixty (60) subjects will be enrolled and treated with Lithoplasty to yield thirty (51) evaluable subjects complete the study assuming a 15% lost to follow-up rate.

Description:

Shockwave Medical, Inc. intends to conduct a prospective, single-arm, multi-center, clinical study designed to evaluate the safety and performance of the Shockwave Lithoplasty™ System in subjects with moderate to heavily calcified peripheral arteries with 3.50mm to 7.0mm reference vessel diameter at the target site. The Shockwave Lithoplasty™ System is indicated for lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. Up to sixty (60) subjects will be enrolled at up to 8 centers in Europe and New Zealand to yield at least 51 evaluable subjects (assuming a lost-to-follow up rate of 15%).

Subjects will be evaluated at discharge, 30 days, 6 months, and 12 months after enrollment/index procedure.

Primary endpoints include safety and efficacy. Safety is a composite of new-onset Major Adverse Events through 30 days. Efficacy is target lesion patency at 12 months by duplex ultrasound defined as freedom from ≥50% restenosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 2016
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject is able and willing to comply with all assessments in the study.

2. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.

3. Age of subject is >18.

4. Rutherford Clinical Category 2, 3, or 4.

5. Resting ankle-brachial index (ABI) of =0.90, or =0.75 after exercise, of the target leg.

6. Estimated life expectancy >1 year.

Angiographic Inclusion Criteria:

1. Subject is a suitable candidate for angiography and endovascular intervention in the opinion of the investigator or per hospital guideline.

2. Target lesion that is located in a native de novo superficial femoral artery (SFA) or popliteal artery (popliteal artery extends to and ends proximal to the ostium of the anterior tibial artery).

3. Target lesion reference vessel diameter is between 3.50mm and 7.0mm by visual estimate.

4. Target zone is =150mm in length. Target lesion can be all or part of the 150mm zone.

5. Target lesion is =70% stenosis by investigator via visual estimate.

6. Subject has at least one patent tibial vessel on the target leg with runoff to the ankle (not supported by collateral circulation.) Tibial vessel patency is defined as no stenosis >50%.

7. Ability to pass the guidewire across the atherosclerotic lesion.

8. No evidence of aneurysm or acute or chronic thrombus in target vessel.

9. Calcification is at least moderate. (Presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending = 50% the length of the lesion.)

Exclusion Criteria:

1. Rutherford Clinical Category 5 and 6.

2. Subject has active infection in the target leg.

3. Planned major amputation of the target leg (transmetatarsal or higher).

4. The use of chronic total occlusion (CTO) re-entry devices.

5. CTOs greater than 80 mm in length.

6. Any in-stent restenosis within the target zone.

7. Lesions within 10 mm of ostium of the SFA.

8. Highly tortuous arteries (bends greater than 30 degrees over the arc length of the balloon).

9. Target lesion within native or synthetic vessel grafts.

10. History of prior endovascular or surgical procedure on the index limb within the past 30 days.

11. Subject has significant stenosis (>50% stenosis) or occlusion of inflow tract before target treatment zone (e.g. iliac or common femoral) not successfully treated with Plain old Balloon Angioplasty (POBA) or stent and without complications.

12. Subject requires treatment of a peripheral lesion on the ipsilateral limb distal and beyond the 150mm target zone at the time of the enrollment/index procedure.

13. Subject has a known coagulopathy or has a bleeding diatheses, thrombocytopenia with platelet count less than 100,000/microliter, or International Normalized Ratio (INR) >1.5.

14. Subject in whom antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated.

15. Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.

16. Subject has known allergy to urethane, nylon, or silicone.

17. Myocardial infarction within 60 days prior to enrollment.

18. History of stroke within 60 days prior to enrollment.

19. History of unstable coronary artery disease or other uncontrollable comorbidity resulting in hospitalization within the last 60 days prior to enrollment.

20. History of thrombolytic therapy within two weeks of enrollment.

21. Subject has acute or chronic renal disease (e.g., as measured by a serum creatinine of >2.5 mg/dL or >220 umol/L), or on dialysis.

22. Subject is pregnant or nursing.

23. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.

24. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Device:
• Shockwave Lithoplasty System

Locations

Country	Name	City	State
Austria	Universitätsklinikum LKH Graz	Graz
Austria	Hanusch Krankenhaus	Vienna
Austria	Medizinische Universitat Wien	Vienna
Germany	Universitäts-Herzzentrum Freiburg & Bad Krozingen	Bad Krozingen
Germany	University Leipzig Medical Centre	Leipzig
Germany	St. Franziskus Hospital	Munster
Germany	RoMed Klinikum Rosenheim	Rosenheim
New Zealand	Auckland City Hospital	Auckland

Sponsors (1)

Lead Sponsor	Collaborator
Shockwave Medical, Inc.

Countries where clinical trial is conducted

Austria,  Germany,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness Endpoint Defined as Number of Participants withTarget Lesion Patency by Duplex Ultrasound Defined as Freedom From =50% Restenosis		12 months post-procedure
Primary	Safety Endpoint Defined as Composite of New-onset Major Adverse Events (MAEs)	Need for emergency surgical revascularization of target limb. Unplanned target limb amputation (above the ankle). Symptomatic thrombus or distal emboli, defined as clinical signs or symptoms of thrombus or distal emboli detected in the treated limb in the area of the treated lesion or distal to the treated lesion after the index procedure and results in extended hospitalization or noted angiographically, and requiring mechanical or pharmacologic means to improve flow and results in extended hospitalization.; Perforations and dissections of grade D or greater that require an intervention to resolve, including bail-out stenting.	Within 30 days following procedure
Secondary	Safety Measured by Number of Participants With Freedom From Major Adverse Events (MAEs)		12 months
Secondary	Secondary Endpoint of Acute Procedural Success Achieved in Number of Participants	The ability of the Shockwave Lithoplasty System to achieve a post-Shockwave residual diameter stenosis of <50% (with or without adjunctive Percutaneous Transluminal Angioplasty (PTA) therapy) as assessed by quantitative angiography via core lab evaluation.; The ability of the Shockwave Lithoplasty System to achieve a post-Shockwave residual diameter stenosis of <50% (without adjunctive PTA therapy) as assessed by quantitative angiography via core lab evaluation.	Day of Procedure
Secondary	Secondary Patency Measured by Number of Participants With Target Lesion Patency by Duplex Ultrasound Defined as Freedom From =50% Restenosis.		6 months
Secondary	Secondary Patency Measured by Number of Participants With Target Lesion Patency (Without Adjunctive PTA) by Duplex Ultrasound Defined as Freedom From =50% Restenosis.		12 months
Secondary	Clinical Success - Improvement of Ankle-Brachial Index (ABI) of the Target Limb.	The ankle-brachial pressure index or ankle-brachial index is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm. It has been shown to be a specific and sensitive metric for the diagnosis of Peripheral Arterial Disease (PAD).	6 months
Secondary	Clinical Success - Improvement of Ankle-Brachial (ABI) of the Target Limb.	The ankle-brachial pressure index or ankle-brachial index is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm. It has been shown to be a specific and sensitive metric for the diagnosis of Peripheral Arterial Disease (PAD).	12 months
Secondary	Clinical Success	Change in Rutherford Clinical Category at from Baseline to 6 months.; There are seven stages to consider: Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.; Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene	6 months
Secondary	Clinical Success	Change in Rutherford Clinical Category from Baseline to12 months.; There are seven stages to condsider: Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.; Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene	12 months
Secondary	Clinical Success	Change in Rutherford Clinical Category from Baseline to 30 days; There are seven stages to condsider: Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.; Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene	30 days